Reducing cardiovascular risk in diabetes

Journal of Hypertension

Volumn 25, Issue SUPPL. 1, 2007, Pages

  Marre, Michel ^a,b  

^a BICHAT HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Cardiovascular diseases; Diabetes; Microangiopathy

Indexed keywords

EID: 34848834450     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/01.hjh.0000271505.69949.9d     Document Type: Article

References (22)

1. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4, 400 patients observed between 1947 and 1973 [in French]. Diabete Metab 1977;3:97-107; 173-182; 245-256. (Pubitemid 8128361)
2. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
3. Mauer SM, Steffes MW, Sutherland DE, Najarian S, Michael AF, Brown DM. Studies of the rate of regression of the glomerular lesions in diabetic rats treated with pancreatic islet transplantation. Diabetes 1975;24:280-285.
4. Spiro RG. Search for a biochemical basis of diabetic microangiopathy. Diabetologia 1976;12:1-14.
5. Parving HH, Viberti GC, Keen H, Christiansen JS, Lassen NA. Hemodynamic factors in the genesis of diabetic microangiopathy. Metabolism 1983;32:943-949. (Pubitemid 13051146)
6. Marre M, Fabbri P, Berrut G, Bouhanick B. The concept of incipient diabetic nephropathy and effect of early antihypertensive intervention, chapter 40, figure 40-1. In: Mogensen CE, editor. The kidney and hypertension, 4th ed. Boston/Dordrecht/London: Kluwer Academic Publishers; 1998. pp. 399-407.
7. Kohner EM, Hamilton AM, Saunders SJ, Sutcliffe BA, Bulpitt CJ. The retinal blood flow in diabetes. Diabetologia 1975;11:27-33.
8. Tesfaye S, Malik R, Harris N, Jakubowski JJ, Mody C, Rennie IG, Ward JG. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 1996;39:329-335. (Pubitemid 26066803)
9. Brownlee M. Glycation and diabetic complications. Diabetes 1994;43:836-841. (Pubitemid 24166362)
10. Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 2005;112:179-184. (Pubitemid 40982299)
11. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987;36:808-812. (Pubitemid 17145301)
12. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412. (Pubitemid 30609442)
13. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, et al. The EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus (EUCLID) Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998;351:28-31. (Pubitemid 28020163)
14. Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, Boulton AJ. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352:1978-1981. (Pubitemid 29000865)
15. American Diabetes Association (ADA). Standards of medical care in diabetes: position statement. Diabetes Care 2006;29(Suppl. 1):S4-S42.
16. Tapp RJ, Zimmet PZ, Harper CA, de Courten MP, McCarty DJ, Balkau B, et al., the AusDiab Study Group. Diagnostic thresholds for diabetes: the association of retinopathy and albuminuria with glycaemia. Diabetes Res Clin Pract 2006;73:315-321. E-pub 27 April 2006. (Pubitemid 44107590)
17. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study. Lancet 1980;1:1373-1376. (Pubitemid 10069461)
18. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-240. (Pubitemid 29056916)
19. Hillier TA, Fagot-Campagna A, Eschwège E, Vol S, Cailleau M, Balkau B. Weight change and changes in the metabolic syndrome as the French population moves towards overweight: The D. E. S. I. R. Cohort. Int J Epidemiol 2006;35:190-196. (Pubitemid 43205468)
20. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
21. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486-494. (Pubitemid 37430502)
22. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653. (Pubitemid 41817713)